Nintedanib Eg

Nintedanib, the active ingredient in Nintedanib Eg, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is classified as an antifibrotic agent and is indicated for the treatment of idiopathic pulmonary fibrosis and for use in combination therapy for certain non‑small cell lung cancers in adult patients.

GNH USA supplies Nintedanib Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable sourcing for clinical and research needs and ensuring compliance with regulatory standards.

Nintedanib acts on fibrotic and oncogenic pathways, making it useful in several pulmonary and cancer indications. - Idiopathic pulmonary fibrosis: reduces the rate of forced vital capacity decline. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung function. - Non‑small cell lung cancer (in combination with chemotherapy): improves progression‑free survival.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea and vomiting: gastrointestinal upset that may affect appetite. - Decreased appetite: reduced food intake leading to weight loss. - Elevated liver enzymes: mild transaminase increases detected on routine labs.

Serious or Rare Side Effects: - Severe liver injury: jaundice, hepatic failure requiring monitoring. - Major bleeding events: gastrointestinal or intracranial hemorrhage, especially with anticoagulants. - Cardiovascular complications: hypertension, arterial thrombotic events, or heart failure. - Gastrointestinal perforation: rare but potentially life‑threatening. - Severe infections: opportunistic infections in immunocompromised patients.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks. - Liver monitoring: perform baseline and periodic liver function tests. - Cardiovascular assessment: evaluate blood pressure and cardiac history. - Bleeding risk: review concomitant anticoagulant or antiplatelet use. - Gastrointestinal symptoms: advise patients to report persistent diarrhea or abdominal pain. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nintedanib can interact with several drug classes, influencing its exposure or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase nintedanib plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): may heighten bleeding risk.

Moderate Interactions (Monitor Closely): - P‑gp inhibitors (e.g., verapamil, amiodarone): modestly raise nintedanib concentrations. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal bleeding potential. - Diuretics and antihypertensives: may exacerbate hypotension or electrolyte disturbances.